The use of micafungin in neonates and children: A systematic review
Keywords:
micafungin, neonates, children, cost-effectivenessAbstract
BACKGROUNG: About 10% of newborns under 1000 g have problems related to candidiasis. The mortality rate is still very high today, and new types of drugs are used for the treatment. To this end, the researcher conducts a systematic review concerning the clinical use of the micafungin drug in children and its impact regarding cost-effectiveness.
METHODS: The research used the PRISMA statements methodology to include all clinical and economic findings concerning the treatment of candidiasis through micafungin in infants and children.
RESULTS: The research considers 13 clinical sources related to the use of micafungin belonging to the echinocandin family and a source of an economic nature. As highlighted by the research, micafungin is used in neonates for candida treatment with doses ranging from 0.4 to 10 mg/kg/ day on average for 15 days, and in children, the dose decreases slightly between 0.8 and 7.7 mg/kg/ day with a treatment period between 5 and 45 days.
CONCLUSIONS: The use and efficacy of micafungin are features validated by several international clinical trials, success rates and conclusions confirm its validity. The analysis present in the literature on costs highlights how this disease is associated with higher costs due to the high number of days of hospitalization and for the administration of the drug.
Downloads
References
Arrieta, A. C., Maddison, P., & Groll, A. H. (2011). Safety of micafungin in pediatric clinical trials. The Pediatric Infectious Disease Journal, 30(6), e97–e102. https://doi.org/10.1097/INF.0b013e3182127eaf
Benjamin, D. K., DeLong, E., Cotten, C. M., Garges, H. P., Steinbach, W. J., & Clark, R. H. (2004). Mortality Following Blood Culture in Premature Infants: Increased with Gram-negative Bacteremia and Candidemia, but Not Gram-positive Bacteremia. Journal of Perinatology, 24(3), 175–180. https://doi.org/10.1038/sj.jp.7211068
Benjamin, D. K., Stoll, B. J., Fanaroff, A. A., McDonald, S. A., Oh, W., Higgins, R. D., Duara, S., Poole, K., Laptook, A., & Goldberg, R. (2006). Neonatal Candidiasis Among Extremely Low Birth Weight Infants: Risk Factors, Mortality Rates, and Neurodevelopmental Outcomes at 18 to 22 Months. Pediatrics, 117(1), 84–92. https://doi.org/10.1542/peds.2004-2292
Benjamin, D. K., Stoll, B. J., Gantz, M. G., Walsh, M. C., Sánchez, P. J., Das, A., Shankaran, S., Higgins, R. D., Auten, K. J., Miller, N. A., Walsh, T. J., Laptook, A. R., Carlo, W. A., Kennedy, K. A., Finer, N. N., Duara, S., Schibler, K., Chapman, R. L., Van Meurs, K. P., … Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. (2010). Neonatal candidiasis: Epidemiology, risk factors, and clinical judgment. Pediatrics, 126(4), e865-873. https://doi.org/10.1542/peds.2009-3412
Blyth, C. C., Chen, S. C. A., Slavin, M. A., Serena, C., Nguyen, Q., Marriott, D., Ellis, D., Meyer, W., & Sorrell, T. C. (2009). Not Just Little Adults: Candidemia Epidemiology, Molecular Characterization, and Antifungal Susceptibility in Neonatal and Pediatric Patients. Pediatrics, 123(5), 1360–1368. https://doi.org/10.1542/peds.2008-2055
Bochennek, K., Balan, A., Müller-Scholden, L., Becker, M., Farowski, F., Müller, C., Groll, A. H., & Lehrnbecher, T. (2015). Micafungin twice weekly as antifungal prophylaxis in paediatric patients at high risk for invasive fungal disease. The Journal of Antimicrobial Chemotherapy, 70(5), 1527–1530. https://doi.org/10.1093/jac/dku544
Buck M. (2014). Micafungin Use in the Treatment of Neonatal and Pediatric Fungal Infections. 4.
Greenberg, R. G., & Benjamin, D. K. (2014). Neonatal candidiasis: Diagnosis, prevention, and treatment. The Journal of Infection, 69 Suppl 1, S19-22. https://doi.org/10.1016/j.jinf.2014.07.012
Heresi, G. P., Gerstmann, D. R., Reed, M. D., van den Anker, J. N., Blumer, J. L., Kovanda, L., Keirns, J. J., Buell, D. N., & Kearns, G. L. (2006). The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. The Pediatric Infectious Disease Journal, 25(12), 1110–1115. https://doi.org/10.1097/01.inf.0000245103.07614.e1
Hill, A. V. S. (1998). The Immunogenetics of Human Infectious Diseases. Annual Review of Immunology, 16(1), 593–617. https://doi.org/10.1146/annurev.immunol.16.1.593
Hope, W. W., Smith, P. B., Arrieta, A., Buell, D. N., Roy, M., Kaibara, A., Walsh, T. J., Cohen-Wolkowiez, M., & Benjamin, D. K. (2010). Population Pharmacokinetics of Micafungin in Neonates and Young Infants. Antimicrobial Agents and Chemotherapy, 54(6), 2633–2637. https://doi.org/10.1128/AAC.01679-09
Kawaguchi, C., Arai, I., Yasuhara, H., Sano, R., Nishikubo, T., & Takahashi, Y. (2009). Efficacy of micafungin in treating four premature infants with candidiasis. Pediatrics International, 51(2), 220–224. https://doi.org/10.1111/j.1442-200X.2008.02726.x
Kobayashi, C., Hanadate, T., Niwa, T., Yoshiyasu, T., So, M., & Matsui, K. (2015). Safety and Effectiveness of Micafungin in Japanese Pediatric Patients: Results of a Postmarketing Surveillance Study. Journal of Pediatric Hematology/Oncology, 37(5), e285–e291. https://doi.org/10.1097/MPH.0000000000000343
Kovanda, L. L., Walsh, T. J., Benjamin, D. K., Arrieta, A., Kaufman, D. A., Smith, P. B., Manzoni, P., Desai, A. V., Kaibara, A., Bonate, P. L., & Hope, W. W. (2018). Exposure-Response Analysis of Micafungin in Neonatal Candidiasis: Pooled Analysis of Two Clinical Trials. The Pediatric Infectious Disease Journal, 37(6), 580–585. https://doi.org/10.1097/INF.0000000000001957
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009). The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. PLoS Medicine, 6(7), e1000100. https://doi.org/10.1371/journal.pmed.1000100
Makhoul, I. R., Sujov, P., Smolkin, T., Lusky, A., & Reichman, B. (2002). Epidemiological, Clinical, and Microbiological Characteristics of Late-Onset Sepsis Among Very Low Birth Weight Infants in Israel: A National Survey. Pediatrics, 109(1), 34–39. https://doi.org/10.1542/peds.109.1.34
Manzoni, P., Wu, C., Tweddle, L., & Roilides, E. (2014). Micafungin in premature and non-premature infants: A systematic review of 9 clinical trials. The Pediatric Infectious Disease Journal, 33(11), e291-298. https://doi.org/10.1097/INF.0000000000000434
Maximova, N., Schillani, G., Simeone, R., Maestro, A., & Zanon, D. (2017). Comparison of Efficacy and Safety of Caspofungin Versus Micafungin in Pediatric Allogeneic Stem Cell Transplant Recipients: A Retrospective Analysis. Advances in Therapy, 34(5), 1184–1199. https://doi.org/10.1007/s12325-017-0534-7
Queiroz-Telles, F., Berezin, E., Leverger, G., Freire, A., van der Vyver, A., Chotpitayasunondh, T., Konja, J., Diekmann-Berndt, H., Koblinger, S., Groll, A. H., Arrieta, A., & Micafungin Invasive Candidiasis Study Group. (2008). Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: Substudy of a randomized double-blind trial. The Pediatric Infectious Disease Journal, 27(9), 820–826. https://doi.org/10.1097/INF.0b013e31817275e6
Santolaya, M. E., Alvarado Matute, T., de Queiroz Telles, F., Colombo, A. L., Zurita, J., Tiraboschi, I. N., Cortes, J. A., Thompson-Moya, L., Guzman-Blanco, M., Sifuentes, J., Echevarría, J., & Nucci, M. (2013). Recommendations for the management of candidemia in neonates in Latin America. Revista Iberoamericana de Micología, 30(3), 158–170. https://doi.org/10.1016/j.riam.2013.05.012
Santolaya Maria E., de Queiroz Telles F., Alvarado Matute T., Colombo A. L., Zurita J., J., Tiraboschi, I. N., Cortes, J. A., Thompson-Moya, L., Guzman-Blanco, M., Sifuentes, J., Echevarría, J., & Nucci, M. (2013). Recommendations for the management of candidemia in children in Latin America. Revista Iberoamericana de Micología, 30(3), 171–178. https://doi.org/10.1016/j.riam.2013.05.010
Smith, P. B., Walsh, T. J., Hope, W., Arrieta, A., Takada, A., Kovanda, L. L., Kearns, G. L., Kaufman, D., Sawamoto, T., Buell, D. N., & Benjamin, D. K. (2009). Pharmacokinetics of an Elevated Dosage of Micafungin in Premature Neonates. The Pediatric Infectious Disease Journal, 28(5), 412–415. https://doi.org/10.1097/INF.0b013e3181910e2d
Steinbach, W. J. (2016). Pediatric Invasive Candidiasis: Epidemiology and Diagnosis in Children. Journal of Fungi, 2(1). https://doi.org/10.3390/jof2010005
Styczynski, J., Czyzewski, K., Wysocki, M., Zajac-Spychala, O., Wachowiak, J., Ociepa, T., Urasinski, T., Gryniewicz-Kwiatkowska, O., Kolodziejczyk-Gietka, A., Dembowska-Baginska, B., Perek, D., Salamonowicz, M., Hutnik, L., Matysiak, M., Siewiera, K., Frackiewicz, J., Kalwak, K., Badowska, W., Malas, Z., … Gil, L. (2016). Micafungin in invasive fungal infections in children with acute leukemia or undergoing stem cell transplantation. Leukemia & Lymphoma, 57(10), 2456–2459. https://doi.org/10.3109/10428194.2016.1143937
Sucher, A. J., Chahine, E. B., & Balcer, H. E. (2009). Echinocandins: The newest class of antifungals. The Annals of Pharmacotherapy, 43(10), 1647–1657. https://doi.org/10.1345/aph.1M237
Zaoutis, T. (2010). Candidemia in children. Current Medical Research and Opinion, 26(7), 1761–1768. https://doi.org/10.1185/03007995.2010.487796
Zaoutis, T. E., Argon, J., Chu, J., Berlin, J. A., Walsh, T. J., & Feudtner, C. (2005). The Epidemiology and Attributable Outcomes of Candidemia in Adults and Children Hospitalized in the United States: A Propensity Analysis. Clinical Infectious Diseases, 41(9), 1232–1239. https://doi.org/10.1086/496922
Zilberger M. D., & Shorr A. F. (2010). Understanding cost-effectiveness. Clinical Microbiology and Infection, 16(12), 1707–1712. https://doi.org/10.1111/j.1469-0691.2010.03331.x
Published
How to Cite
Issue
Section
Copyright (c) 2020 European journal of volunteering and community-based projects
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
